No one, and I mean no one, understands drug pricing and the policies around regulating them like Stacie Dusetzina, PhD, from the Department of Health Policy at Vanderbilt University School of Medicine, does. So, I was fortunate to have her as my guest on the podcast to discuss the “desensitization” of society to cancer prescription drug costs, the role of advancing science in research and development and drug approvals for rare diseases, the H.R.3 bill in front of Congress, and solutions proposed by politicians for inflated Medicare Part D spending, among other topics.
Everyone is impacted by drug prices; you want to learn more about where we go from here; listening to Dr. Dusetzina is key.
This podcast is produced by the Journal of Clinical Pathways.
Dr. Pedro Barata, Director of the Clinical Genitourinary Medical Oncology Research Program at UH Seidman Cancer Center, provides an exclusive round-up of the most groundbreaking and practice-changing research unveiled at the ASCO GU 2024 meeting. With expertise and insight, he delves into pivotal studies such as CheckMate 914 Part B and KEYNOTE-564, exploring their implications
Dr. LaBelle elucidates the complexities of sickle cell disease, unraveling the devastating impact it has on individuals. The episode delves into various treatments and approaches to combat this formidable disease, including bone marrow transplant and the groundbreaking use of CRISPR-Cas9 technology. LaBelle shares insights into the recent research breakthroughs, citing the remarkable research report published
n this poignant episode, USA Today investigative journalist Emily Le Coz unravels the heart-wrenching narrative of Ashleigh Anderson, a CVS pharmacist whose tragic demise serves as a cautionary tale of overwhelming stress in the workplace. Emily shares her motivations behind delving into the pervasive issue of burnout in retail pharmacy and sheds light on the
